On June 16, 2022, Haemonetics Corporation announced that Michelle L. Basil, Executive Vice President, General Counsel has decided to transition from the Company effective October 31, 2022. Ms. Basil has agreed to remain in her current role through October 31, 2022 to ensure a seamless transition while the Company conducts a search for her successor.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
96.49 USD | -0.90% | +3.47% | +12.84% |
May. 10 | Barrington Research Raises Price Target on Haemonetics to $107 From $105, Keeps Outperform Rating | MT |
May. 09 | Haemonetics Seeks Acquisitions | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.84% | 4.95B | |
-4.98% | 181B | |
+2.84% | 112B | |
-2.68% | 67.92B | |
+4.53% | 50.1B | |
+8.00% | 44.27B | |
+9.39% | 40.41B | |
+25.30% | 31.95B | |
-0.17% | 25.82B | |
+17.27% | 25.29B |
- Stock Market
- Equities
- HAE Stock
- News Haemonetics Corporation
- Haemonetics Corporation Announces Michelle L. Basil, Executive Vice President, General Counsel Has Decided to Transition, Effective October 31, 2022